Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels. Their conversation highlights a need for patient education and shared decision-making.
Division of Digestive Diseases and Nutrition
Department of Internal Medicine
University of Kentucky
This program has been made available online.
Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)
Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment
Clinical Care Options (CCO) expert audio: Dr Pietro Lampertico discusses the importance of continued HBV monitoring in patients without indications for immediate treatment
Clinical Care Options (CCO) commentary from Maria Buti, MD, on the interplay between HBV infection and pregnancy